Table 1 Binding kinetics of antibodies to immobilized EGFRvIII.
From: Targeting cancer expressed EGFR with a humanized monoclonal antibody
Ligand | Antibody | Variable Chain combination | ka (1/Ms) | kd (1/s) | KD (nM) |
|---|---|---|---|---|---|
EGFRvIII | A1 | VH + VL | 3.38E + 05 | 8.55E-04 | 2.53 |
EGFRvIII | A2 | VH1 + VL1 | 2.09E + 05 | 9.48E-04 | 4.53 |
EGFRvIII | A3 | VH1 + VL2 | 1.89E + 05 | 1.01E-03 | 5.35 |
EGFRvIII | A4 | VH1 + VL3 | 2.85E + 05 | 9.18E-04 | 3.22 |
EGFRvIII | A5 | VH2 + VL1 | 2.01E + 05 | 8.86E-04 | 4.4 |
EGFRvIII | A6 | VH2 + VL2 | 1.86E + 05 | 7.08E-04 | 3.81 |
EGFRvIII | A7 | VH2 + VL3 | 2.20E + 05 | 8.70E-04 | 3.95 |
EGFRvIII | A8 | VH3 + VL1 | 2.06E + 05 | 6.66E-04 | 3.24 |
EGFRvIII | A9 | VH3 + VL2 | 1.90E + 05 | 7.29E-04 | 3.84 |
EGFRvIII | A10 | VH3 + VL3 | 2.44E + 05 | 6.16E-04 | 2.53 |
EGFRvIII | B1 | VH + VL-DA | 3.74E + 05 | 7.46E-04 | 2 |
EGFRvIII | B2 | VH + VL-EG | 3.63E + 05 | 8.92E-04 | 2.46 |
EGFRvIII | B3 | VH2 + VL2-DA | 2.08E + 05 | 8.27E-04 | 3.97 |
EGFRvIII | B4 | VH2 + VL1-DA | 2.41E + 05 | 7.16E-04 | 2.97 |
EGFRvIII | B5 | VH3 + VL1-DA | 2.34E + 05 | 5.95E-04 | 2.54 |
